We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fifth time's the charm for infant respiratory distress drug.
- Authors
Katsnelson, Alla
- Abstract
The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Surfaxin, which is manufactured by Discovery Labs. Surfaxin is a peptide therapy indicated for respiratory distress in preterm infants. In Europe, Surfaxin was able to secure an orphan drug status for cystic fibrosis. One of the advantages of Surfaxin is its potential for a new kind of delivery.
- Subjects
UNITED States; DRUG approval; UNITED States. Food &; Drug Administration; DISCOVERY Laboratories Inc.; PEPTIDES; TREATMENT of premature infant diseases; THERAPEUTICS
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 5, p380
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0512-380c